Tango Therapeutics (TNGX)

1 big move explained, newest first · Biotech

  1. Tango Therapeutics falls 12% despite strong pancreatic cancer data

    Tango's pancreatic cancer combination shrank tumors in 82% of patients, but the stock fell after a run-up into the data, with a Phase 3 trial still more than a year away.